Announcements Trials

Browse Landscape

Phase

Phase 3 2 Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Hematologic Neoplasms 2 Recurrence 1 Leukemia, Myeloid, Acute 1 Leukemia 1 Hematologic Tumors 1

Interventions

Cyclophosphamide 41 fludarabine 31 Dexamethasone 27 venetoclax 25 Cytarabine 22 Rituximab 16 pembrolizumab 15 fludarabine phosphate 14 Filgrastim 12 Etoposide 12 Lenalidomide 11 Vincristine 10 Gemcitabine 10 Azacitidine 10 pomalidomide 9 Interleukin-2 9 Granulocyte Colony-Stimulating Factor 9 Doxorubicin 9 Calcium Dobesilate 9 carfilzomib 8 Topotecan 8 Nivolumab 8 Methotrexate 8 Everolimus 8 Decitabine 8 Bortezomib 8 Melphalan 7 Cisplatin 7 Vorinostat 6 Injections 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Recurrence × Homoharringtonine × Clear all

NCT04926285 2026-03-16

VEN-OM

University of Illinois at Chicago

Phase 1 Completed

Other hematologic neoplasm

Recurrence, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡